Welcome to our dedicated page for Cocrystal Pharma SEC filings (Ticker: COCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides organized access to Cocrystal Pharma, Inc. (Nasdaq: COCP) SEC filings, allowing readers to review the company’s official regulatory disclosures alongside AI-generated highlights. Cocrystal is a clinical-stage biotechnology company developing structure-based antiviral therapeutics targeting influenza viruses, coronaviruses, noroviruses and hepatitis C viruses, and its filings describe how these programs are financed and advanced.
Here you can review current reports on Form 8-K, which Cocrystal uses to disclose material events. Recent 8-K filings have reported quarterly financial results, FDA Investigational New Drug (IND) clearance and a Study May Proceed Letter for a Phase 1b human challenge study with CDI-988, an oral broad-spectrum 3CL protease inhibitor for norovirus, as well as an NIH Small Business Innovation Research (SBIR) Phase I award supporting an influenza A/B polymerase complex program. Other 8-Ks detail registered direct offerings and private placements of common stock and warrants, including insider participation and the terms of securities purchase agreements.
The page also links to registration statements such as the Form S-1 filed in 2025, which registers the resale of shares issuable upon exercise of outstanding warrants originally issued in a private placement concurrent with a registered direct offering. These documents outline the company’s capital structure, risk factors and use of proceeds related to COCP shares and associated warrants.
Stock Titan’s tools surface AI-powered summaries of lengthy filings, helping users quickly understand key points from 8-Ks, S-1 registration statements and other reports without reading every page. Investors can also track disclosures related to equity financings, warrant terms and listing information for COCP on The Nasdaq Capital Market. This filings hub is intended as a starting point for deeper review of Cocrystal’s official SEC documents on EDGAR.
Cocrystal Pharma director Richard C. Pfenniger Jr. reported receiving a grant of non-qualified stock options on January 9, 2026. The award covers 16,410 stock options with an exercise price of $1.10 per share, giving him the right to buy Cocrystal Pharma common stock at that price in the future. The options were granted under the company’s 2025 Equity Incentive Plan.
These options vest over time, meaning he earns the right to exercise them gradually. One-half of the grant will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting on March 31, 2027, as long as he continues to serve as a director on each vesting date.
Cocrystal Pharma, Inc. reported that President and Co-CEO Sam Lee received a grant of 49,229 non-qualified stock options on January 9, 2026 under the company’s 2025 Equity Incentive Plan. The options give the right to buy common stock at an exercise price of $1.1 per share and were acquired at no cost.
According to the vesting schedule, one-half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting March 31, 2027, as long as Lee continues to serve as an officer on each vesting date. All 49,229 derivative securities are reported as directly owned following this grant.
Cocrystal Pharma, Inc. reported that director Fred Hassan received a grant of 16,410 non-qualified stock options on January 9, 2026. The options have an exercise price of $1.10 per share, were granted under the company’s 2025 Equity Incentive Plan, and were approved by the Compensation Committee under Rule 16b-3. One-half of the grant vests and becomes exercisable on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting on March 31, 2027, as long as Hassan continues to serve as a director on each vesting date.
Cocrystal Pharma Co-CEO and CFO Martin James Joseph received a grant of 49,229 non-qualified stock options on January 9, 2026. These stock options give him the right to buy up to 49,229 shares of Cocrystal Pharma common stock at an exercise price of $1.1 per share, and they expire on January 9, 2036.
Half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting March 31, 2027, as long as he continues to serve as an officer of the company on each vesting date. The grant was approved by the board’s Compensation Committee under the company’s 2025 Equity Incentive Plan and was reported as a direct beneficial holding.
Cocrystal Pharma, Inc. reported that director and 10% owner Phillip Frost received a grant of stock options. On January 9, 2026, he was awarded 24,615 non-qualified stock options to buy Cocrystal common stock at an exercise price of $1.10 per share, for no upfront cost. These options were approved by the company’s Compensation Committee under the 2025 Equity Incentive Plan.
Half of the options vest and become exercisable on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting March 31, 2027, as long as Frost continues to serve as a director on each vesting date. The filing notes that this report does not include securities owned directly by OPKO Health, Inc., for which Frost disclaims beneficial ownership except for any pecuniary interest.
Cocrystal Pharma director Anthony J. Japour reported a new equity award. On January 9, 2026, he received non-qualified stock options to purchase 16,410 shares of Cocrystal Pharma common stock at an exercise price of $1.1 per share under the company’s 2025 Equity Incentive Plan. These options were approved by the Compensation Committee and reported as directly owned.
The options vest over time: one-half becomes exercisable on January 9, 2027, and the remaining half vests in eight equal quarterly installments beginning March 31, 2027, as long as he continues to serve as a director on each vesting date.
Cocrystal Pharma director Steven D. Rubin reported receiving non-qualified stock options for 16,410 shares of Cocrystal Pharma common stock on January 9, 2026. The options have an exercise price of $1.10 per share and were granted under the company’s 2025 Equity Incentive Plan, approved by the Compensation Committee of the Board.
Half of these options vest and become exercisable on January 9, 2027. The remaining half vests in eight equal quarterly installments starting March 31, 2027, as long as Rubin continues to serve as a director on each vesting date. After this grant, he beneficially owns stock options for 16,410 shares, held directly.
Cocrystal Pharma, Inc. reported that an Institutional Review Board at Emory University School of Medicine has approved initiation of a Phase 1b human challenge study with its compound CDI-988. The planned study is designed to evaluate CDI-988 both as a preventive and as a treatment for norovirus infections, a common cause of viral gastroenteritis. The company disclosed this development via a press release furnished as an exhibit to the report.
Cocrystal Pharma (COCP) insider Phillip Frost reported an equity transaction involving 20,000 shares of common stock at a weighted average price of $0.9406 per share on 11/25/2025. The filing shows these shares as indirectly owned through Frost Gamma Investments Trust, bringing his indirect beneficial ownership via that trust to 1,699,551 shares after the transaction. He also reports direct beneficial ownership of 27,100 shares of common stock, which includes shares issuable upon vesting of restricted stock units. Frost is identified as both a director and a 10% owner of Cocrystal Pharma, and the filing clarifies that he disclaims beneficial ownership of certain shares except to the extent of any pecuniary interest.
Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended September 30, 2025 and provided business updates. The company issued a press release on November 14, 2025 detailing these quarterly results and updates, and attached that release as Exhibit 99.1.
The report specifies that the earnings information under Item 2.02 and in Exhibit 99.1 is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless expressly stated.